Multiplexing Technology Supports Autoantibody Studies for Immuno‑Oncology Treatment
Scientists use xMAP® Technology to detect thousands of antibodies in hundreds of samples
At the recent Drug Discovery and Development 2022 conference, Oncimmune® Chief Technical Officer, Hans-Dieter Zucht, gave a presentation about how his company’s scientists are using autoantibodies as biomarkers for a broad range of immuno-oncology studies. This work is made possible with bead-based multiplexing
Zucht pointed out that while immunotherapies have been remarkably effective in fighting cancer, they only work for a small fraction of patients with cancer. Those who do respond well may also suffer from immune-related adverse events to the treatment. There is a pressing need to identify biomarkers that may help stratify patients to ensure immunotherapies are directed to the people most likely to benefit, as well as biomarkers that could predict the likelihood of adverse events. “The concordance and repeatability of these measurements is very high.”Insight into autoantibodies
At Oncimmune, scientists have turned their attention to autoantibodies. This class of antibodies has already been used to elucidate clinically relevant interactions between tumor cells and the immune system. Oncimmune offers the check out this study of patients with metastatic urothelial carcinoma or see our
Learn more about Oncimmune’s approach to multiplexed autoantibody pofiling of patients with metastatic urothelial carcinoma.
Related Content
- Become a Partner [Webpage]
- ® Kit Finder” href=”/kitfinder/”>Browse 1,200+ Partner Kits with xMAP® Kit Finder [Online Tool]
Dialog 